 | Up a level |
2022
Kutsch, Nadine, Fink, Anna Maria, Federhen, Anno, Giza, Adam, Robrecht, Sandra, Stumpf, Janina, Stoltefuss, Andrea, Vehling-Kaiser, Ursula, Koenigsmann, Michael, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Illmer, Thomas, Schlag, Rudolf, Doerfel, Steffen, Gaska, Tobias, Kiehl, Michael G., Fischer, Kirsten, Eichhorst, Barbara and Hallek, Michael (2022). Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry. Blood, 140. S. 9879 - 9882. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
2021
Fuerstenau, Moritz, Giza, Adam, Stumpf, Thomas, Robrecht, Sandra, Maurer, Christian, Linde, Hartmut, Jacobasch, Lutz, Doerfel, Steffen, Aldaoud, Ali, von Tresckow, Julia, Koenigsmann, Michael, Gaska, Tobias, Kaiser, Ulrich, Harich, Hanns-Detlev, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Fink, Anna-Maria (2021). Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia. Am. J. Hematol., 96 (12). S. E457 - 4. HOBOKEN: WILEY. ISSN 1096-8652
2020
Fink, Anna-Maria, Robrecht, Sandra, Bahlo, Jasmin, Fuerstenau, Moritz, Aldaoud, Ali, Hebart, Holger, Jentsch-Ullrich, Kathleen, Doerfel, Steffen, Fischer, Kirsten, Wendtner, Clemens Martin, Noesslinger, Thomas, Ghia, Paolo, Kater, Arnon, Kreuzer, Karl-Anton, Tausch, Eugen, Stilgenbauer, Stephan, Rittgen, Matthias, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2020). Long-term efficacy and safety of maintenance with lenalidomide in patients with chronic lymphocytic leukaemia and a high risk of progression after first-line immunochemotherapy. Leuk. Lymphoma, 61. S. 272 - 274. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403
2017
Fink, Anna Maria, Bahlo, Jasmin, Robrecht, Sandra, Al-Sawaf, Othman, Aldaoud, Ali, Hebart, Holger, Jentsch-Ullrich, Kathleen, Doerfel, Steffen, Fischer, Kirsten, Wendtner, Clemens-Martin, Noesslinger, Thomas, Ghia, Paolo 
ORCID: 0000-0003-3750-7342, Bosch, Francesc ORCID: 0000-0001-9241-2886, Kater, Arnon P., Dohner, Hartmut, Kneba, Michael, Kreuzer, Karl-Anton, Tausch, Eugen, Stilgenbauer, Stephan, Ritgen, Matthias, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael
(2017).
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Lancet Haematol., 4 (10).
S. E475 - 12.
OXFORD:
ELSEVIER SCI LTD.
ISSN 2352-3026
2016
Fink, Anna Maria, Bahlo, Jasmin, Sandra, Robrecht, Al-Sawaf, Othman, Aldaoud, Ali, Hebart, Holger, Jentsch-Ulrich, Kathleen, Doerfel, Steffen, Fischer, Kirsten, Wendtner, Clemens Martin, Noesslinger, Thomas, Ghia, Paolo, Bosch, Francesc ORCID: 0000-0001-9241-2886, Kater, Arnon P., Kreuzer, Karl-Anton, Dohner, Hartmut, Kneba, Michael, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael
(2016).
Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group).
Blood, 128 (22).
WASHINGTON:
AMER SOC HEMATOLOGY.
ISSN 1528-0020
2014
Eichhorst, Barbara, Bahlo, Jasmin, Fink, Anna Maria, Pfreundschuh, Michael, Hebart, Holger, Maschmeyer, Georg, Jentsch-Ulrich, Kathleen, Doerfel, Steffen, Westermann, Anne, Zey, Aline, Fischer, Kirsten, Wendtner, Clemens-Martin, Noesslinger, Thomas, Ghia, Paolo, Bosch, Francesc ORCID: 0000-0001-9241-2886, Kater, Arnon P., Kreuzer, Karl-Anton, Doehner, Hartmut, Stilgenbauer, Stephan, Boettcher, Sebastian and Hallek, Michael
(2014).
Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG).
Blood, 124 (21).
WASHINGTON:
AMER SOC HEMATOLOGY.
ISSN 1528-0020